CI-980 in advanced melanoma and hormone refractory prostate cancer

Investigational New Drugs

Volumn 18, Issue 2, 2000, Pages 187-191

  Ryan, Christopher W ^b   Shulman, Keith L ^b   Richards, Jon M ^b   Kugler, John W ^b   Sosman, Jeffrey A ^a   Ansari, Rafat H ^b   Vokes, Everett E ^b   Vogelzang, Nicholas J ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

Chemotherapy; Clinical trial; Malignant melanoma; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; MIVOBULIN ISETHIONATE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; FEVER; HEARING LOSS; HEART ARRHYTHMIA; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOTENSION; INCONTINENCE; INFECTION; MALE; MELANOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBAMATES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROSTATIC NEOPLASMS; PYRAZINES; PYRIDINES;

EID: 0034063541     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006382014403     Document Type: Article

References (30)

1. Wheeler GP, Bowdon BJ, Werline JA, et al. Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,3-dihydro-3-((N-methyl-anilino)methyl)-pyrido-(3,4-b)pryrazine-7- ylcarbamate (NSC 181928). Cancer Res 42: 791-798, 1982
2. Wheeler GP, Bowdon BJ, Temple CG, et al. Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines. Cancer Res 43: 3567-3575, 1983
3. de Inès C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dlhydropteridine antitumor drug, Cl 980, and by its chiral isomer, NSC 613863. Cancer Res 54: 75-84, 1994
4. Bowdon BJ, Wand WR, Wheeler GP, et al. Comparison of 1,2-dihydropyrido[3,4b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47: 1621-1626, 1987
5. Waud WR, Leopold WR, Elliott WL, et al. Antitumor activity of ethyl 5-amino-1,2-dihydro2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50: 3239-3244, 1990
6. Clinical brochure: CI-980, NSC 613862-August 31, 1990. Brochure available from the National Cancer Institute, Division of Cancer Treatment.
7. Sklarin NT, Lathia CD, Benson L, et al. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs 15: 235-246, 1997
8. Natale R, Waterhouse D, Grove W, et al. Phase I clinical and pharmacokinetic trial of C1980, a novel mitotic inhibitor. Proc Am Soc Clin Oncol 11: 292, 1992 (abstract)
9. Gutheil J, Van Echo D, Egorin M, et al. Phase I study of Cl 980 in patients with refractory malignancies. Proc Annu Meet Assoc Cancer Res 37: Al 129, 1996 (abstract)
10. Rowinski EK, Long GS, Noe DA, et al. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3: 401-407, 1997
11. Stadler WM, Vogelzang NJ, Hofffman P, et al. CI-980 in renal cell and non-small cell lung cancer. Cancer Therapeutics 1: 318-320, 1998
12. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10: 1-10, 1989
13. Pazdur R, Meyers C, Diaz-Canton E, et al. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol 20: 573-576, 1997
14. Kudelka AP, Hasenburg A, Verschraegen CF, et al. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs 9: 405-409, 1998
15. Patel SR, Burgess MA, Papadopolous NE, et al. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs 16: 87-92, 1998
16. Wheeler GP, Bowdon BJ, Werline JA, et al. Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,3-dihydro-3-((N-methyl-anilino)methyl)-pyrido-[3,4-b]pryrazine-7- ylcarbamate (NSC 181928). Cancer Res 42: 791-798, 1982
17. Wheeler GP, Bowdon BJ, Temple CG, et al. Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines. Cancer Res 43: 3567-3575, 1983
18. de Ines C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dlhydropteridine antitumor drug, Cl 980, and by its chiral isomer, NSC 613863. Cancer Res 54: 75-84, 1994
19. Bowdon BJ, Wand WR, Wheeler GP, et al. Comparison of 1,2-dihydropyrido[3,4b]pyrazines (1-deaza-7,8-dihydrop- teridines) with several other inhibitors of mitosis. Cancer Res 47: 1621-1626, 1987
20. Waud WR, Leopold WR, Elliott WL, et al. Antitumor activity of ethyl 5-amino-1,2-dihydro2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50: 3239-3244, 1990
21. Clinical brochure: CI-980, NSC 613862-August 31, 1990. Brochure available from the National Cancer Institute, Division of Cancer Treatment.
22. Sklarin NT, Lathia CD, Benson L, et al. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs 15: 235-246, 1997
23. Natale R, Waterhouse D, Grove W, et al. Phase I clinical and pharmacokinetic trial of C1980, a novel mitotic inhibitor. Proc Am Soc Clin Oncol 11: 292, 1992 (abstract)
24. Gutheil J, Van Echo D, Egorin M, et al. Phase I study of Cl 980 in patients with refractory malignancies. Proc Annu Meet Assoc Cancer Res 37: Al 129, 1996 (abstract)
25. Rowinski EK, Long GS, Noe DA, et al. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res 3: 401-407, 1997
26. Stadler WM, Vogelzang NJ, Hofffman P, et al. CI-980 in renal cell and non-small cell lung cancer. Cancer Therapeutics 1: 318-320, 1998
27. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10: 1-10, 1989
28. Pazdur R, Meyers C, Diaz-Canton E, et al. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol 20: 573-576, 1997
29. Kudelka AP, Hasenburg A, Verschraegen CF, et al. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs 9: 405-409, 1998
30. Patel SR, Burgess MA, Papadopolous NE, et al. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs 16: 87-92, 1998